How does this volume growth compare to the performance of major rivals such as CME Group and Nasdaq?

Answer – Limited Comparative Insight Available

The press release you cited provides only ICE’s July‑2025 trading‑volume and open‑interest data, showing:

• Total average daily volume (ADV) up 12 % year‑over‑year (y/y)
• Open interest (OI) up 12 % y/y, with a record‑high futures component (the excerpt cuts off before the exact figure is given).

These figures are presented in ICE’s “Monthly Statistics Tracking” spreadsheet (link: https://ir.theice.com/ir-resources/supplemental-information). No quantitative or qualitative data about CME Group, Nasdaq, or any other competitors are included in this release.

What That Means for the Comparison

Because the news excerpt does not contain any of the following for CME Group or Nasdaq, we cannot directly compare ICE’s 12 % volume growth to its rivals:

• CME Group’s July 2025 trading volume or open‑interest figures
• Nasdaq’s exchange‑level volume or open‑interest data for the same period
• Any statements from CME or Nasdaq about their own month‑over‑month or year‑over‑year growth rates.

What Can Be Said

• ICE’s performance: A 12 % y/y increase in both average daily volume and open interest indicates a solid expansion of trading activity for ICE in July 2025. This is a notable metric for a market‑infrastructure provider, suggesting higher client activity, broader market participation, or potentially new product launches that attracted more trades.

• Benchmarking: In the derivatives and market‑data space, a double‑digit growth rate is generally viewed as strong, especially in a mature market where many competitors see slower, single‑digit, or even flat/declining volume trends. However, without the actual numbers for CME Group or Nasdaq, we can’t say whether ICE’s 12 % growth outpaces, matches, or lags behind its peers.

Bottom Line

• From the information provided, we can confirm ICE’s 12 % y/y increase in July 2025.
• We lack the necessary data to compare that growth directly to CME Group, Nasdaq, or any other competitor.

If you can supply the relevant monthly statistics for CME Group and Nasdaq (e.g., their July 2025 ADV or OI figures, or any comparable press releases), I’ll gladly perform a side‑by‑side comparison and highlight any relative outperformance or underperformance.